Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AMPH
  • CUSIP:
Key Metrics:
  • Previous Close: $19.35
  • 50 Day Moving Average: $17.71
  • 200 Day Moving Average: $14.52
  • 52-Week Range: $10.50 - $21.16
  • Trailing P/E Ratio: 63.02
  • Foreward P/E Ratio: 34.12
  • P/E Growth: 2.10
  • Market Cap: $875.80M
  • Outstanding Shares: 45,121,000
  • Beta: 1.86
Additional Links:
Companies Related to Amphastar Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $19.60 (0.77% upside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateFirmActionRatingPrice TargetDetails
8/11/2016Piper Jaffray Cos.Reiterated RatingOverweight$22.00View Rating Details
8/9/2016Jefferies GroupBoost Price TargetBuy$16.00 -> $19.00View Rating Details
8/9/2016BMO Capital MarketsReiterated RatingHold$17.00View Rating Details
8/9/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $22.00View Rating Details
3/15/2016Raymond James Financial Inc.Lower Price Target$23.00 -> $18.00View Rating Details
2/19/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.08)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.09)($0.07)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014($0.11)$0.02ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Current Year EPS Consensus Estimate: $0.37 EPS
Next Year EPS Consensus Estimate: $0.57 EPS


Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
News IconPublic access to life-saving overdose drug expands to 79 Ohio counties (NASDAQ:AMPH) - August 30 at 11:29 AM
News IconAttorney general reminds law enforcement of naloxone rebates (NASDAQ:AMPH) - August 29 at 4:06 PM
News IconLaw enforcement officers reminded about Naloxone rebates (NASDAQ:AMPH) - August 28 at 8:16 AM
News IconDeWine reminds law enforcement of Naloxone rebates (NASDAQ:AMPH) - August 27 at 3:27 PM
News IconA-G pushing naloxone reimbursement (NASDAQ:AMPH) - August 27 at 3:27 PM
News IconBiotechnology Stocks: Tiny Biotech Stock Poised to Surge (NASDAQ:AMPH) - August 27 at 8:19 AM
News IconNaloxone rebates help some first responders (NASDAQ:AMPH) - August 26 at 3:29 PM logoIs Amphastar Pharmaceuticals (AMPH) a Great Growth Stock? (NASDAQ:AMPH) - August 24 at 11:45 AM
News IconAmphastar Pharmaceuticals, Inc.'s (AMPH): Prominent Stock of Market - Hot Stocks Point (NASDAQ:AMPH) - August 23 at 8:46 PM logoStocks Tread Water; Facebook Tries To Retake Short-Term Line (NASDAQ:AMPH) - August 22 at 3:31 PM logoETF’s with exposure to Amphastar Pharmaceuticals, Inc. : August 19, 2016 (NASDAQ:AMPH) - August 19 at 4:06 PM logoAMPHASTAR PHARMACEUTICALS, INC. Financials (NASDAQ:AMPH) - August 18 at 3:37 PM
News Icon1 usd to czk Trade-ideas_ amphastar pharmaceuticals (amph) is today’s weak on high relative volume stock – thestreet inr to usd exchange rate (NASDAQ:AMPH) - August 18 at 11:53 AM
News IconWill the Supreme Court Review Whether FDA-Mandated Bioequivalence Testing to Maintain Approval Falls Within the § 271(e)(1) Safe Harbor? (NASDAQ:AMPH) - August 17 at 11:42 AM logoWhy Amphastar Pharmaceuticals (AMPH) Could Be Positioned for a Surge (NASDAQ:AMPH) - August 17 at 11:42 AM logoAmphastar Pharmaceuticals, Inc. :AMPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:AMPH) - August 12 at 12:02 PM
News IconAmphastar Pharmaceuticals Inc 23.6% Potential Upside Now Implied by Needham (NASDAQ:AMPH) - August 11 at 9:21 PM logoEdited Transcript of AMPH earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:AMPH) - August 10 at 3:50 PM logoIs This the Right Time to Add Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to Your Portfolio? - Street Report (NASDAQ:AMPH) - August 10 at 10:27 AM logoTop 5 Pharmaceutical Stocks of 2016 (ABBV, JNJ) (NASDAQ:AMPH) - August 9 at 4:34 PM logoAmphastar Pharmaceuticals : beats 2Q profit forecasts (NASDAQ:AMPH) - August 9 at 12:14 PM logoAMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:AMPH) - August 9 at 12:14 PM logoAmphastar Pharmaceuticals Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended ... - The Wall Street Transcript (NASDAQ:AMPH) - August 8 at 8:57 PM logoAmphastar beats 2Q profit forecasts (NASDAQ:AMPH) - August 8 at 8:57 PM logoQ2 2016 Amphastar Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:AMPH) - August 8 at 8:16 AM
News IconAmphastarbuys UK-based International Medication Systems from UCB PHARMA for $7.7 million (NASDAQ:AMPH) - August 7 at 8:05 AM logoAmphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH - Nasdaq (NASDAQ:AMPH) - August 6 at 3:35 PM logoAmphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH - GlobeNewswire (press release) (NASDAQ:AMPH) - August 4 at 3:33 PM logoAmphastar Pharma (AMPH) Acquires International Medication Systems in $77M Deal (NASDAQ:AMPH) - August 4 at 11:59 AM logo6:03 am Amphastar Pharmaceuticals acquires International Medication Systems from UCB PHARMA GmbH for $7.7 mln (NASDAQ:AMPH) - August 4 at 11:59 AM logoAmphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH (NASDAQ:AMPH) - August 4 at 11:59 AM logoAMPHASTAR PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:AMPH) - August 4 at 11:59 AM logoAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, (NASDAQ:AMPH) - August 2 at 9:06 PM logoAnalysts Actions to Focus: Puma Biotechnology Inc (NYSE:PBYI) , Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Street Updates (NASDAQ:AMPH) - August 1 at 3:29 PM logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMPH-US : August 1, 2016 (NASDAQ:AMPH) - August 1 at 3:29 PM logoAmphastar Pharmaceuticals Inc.: Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold ... - The Wall Street Transcript (NASDAQ:AMPH) - August 1 at 8:24 AM logoAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2016 (NASDAQ:AMPH) - August 1 at 6:21 AM logoBrokers Issue Average Price Target Of 19.20 On Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - FTSE News (NASDAQ:AMPH) - July 29 at 3:30 PM logoMomenta Wins Dismissal Of Blood-Clot Drug Antitrust Suit (NASDAQ:AMPH) - July 28 at 12:09 PM featured highlights: Apogee Enterprises, NTT DOCOMO, Barnes & Noble, Amphaster Pharmaceuticals and Monart Casino & Resort (NASDAQ:AMPH) - July 26 at 9:30 AM
News IconShares Stumbling of Late: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - TGP (NASDAQ:AMPH) - July 22 at 8:29 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - TGP (NASDAQ:AMPH) - July 22 at 11:39 AM
News IconCould Amphastar Pharmaceuticals Inc Lose its Strength? The Stock Reaches 52-Week High - Consumer Eagle (NASDAQ:AMPH) - July 22 at 11:39 AM logoInsiders Selling, Short Interest Growing Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Finance Daily (NASDAQ:AMPH) - July 20 at 11:35 AM
News IconWilliam Peters Sold 2297 shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) in an Insider Trade - Consumer Eagle (NASDAQ:AMPH) - July 19 at 8:54 PM
News IconAmphastar Pharmaceuticals Incorporated (NASDAQ:AMPH) Sellers Increased By 7.97% Their Shorts - Consumer Eagle (NASDAQ:AMPH) - July 19 at 3:28 PM
News IconEquity Roundup: Stock Performance Focus on Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Press Telegraph (NASDAQ:AMPH) - July 19 at 3:28 PM logoOption Market: Amphastar Pharmaceuticals Inc Risk Hits An Inflection Point - CML News (NASDAQ:AMPH) - July 18 at 3:31 PM
News IconReview on Stock Valuation for: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - TGP (NASDAQ:AMPH) - July 18 at 8:18 AM
News IconShare Performance Summary for: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Press Telegraph (NASDAQ:AMPH) - July 18 at 8:18 AM


Amphastar Pharmaceuticals (NASDAQ:AMPH) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff